Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (665 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Pathological processes of coronary arteries that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Artery Disease, Coronary; Artery Diseases, Coronary; Coronary Artery Diseases; Coronary Arteriosclerosis; Arterioscleroses, Coronary; Coronary Arterioscleroses; Arteriosclerosis, Coronary; Atherosclerosis, Coronary.
Where it fits in the MeSH classification
- Broader topics
- Coronary Disease; Arteriosclerosis
- See also
- Atherectomy, Coronary
Related concepts
- Coronary Arteries
Research landscape
PubMed indexes 86,655 records tagged with the MeSH heading “Coronary Artery Disease” (counts retrieved 2026-10-29). 24,471 of them (28.2%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 36,560 records.
Reviews account for 13,948 records (16.1%) and meta-analyses for 2,595. Randomized controlled trials number 4,906 (5.7%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 5,733 |
| 2000-2009 | 19,891 |
| 2010-2019 | 36,560 |
| 2020 onward | 24,471 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 13,948 | 16.1% |
| Meta-analyses | 2,595 | 3.0% |
| Randomized controlled trials | 4,906 | 5.7% |
Method: PubMed query "Coronary Artery Disease"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in cardiovascular medicine
Cardiovascular medicine has an unusually large body of randomized trials, so the type of outcome matters: hard clinical events such as death, heart attack and stroke carry more weight than changes in blood pressure, cholesterol or imaging markers that only predict risk. Observational studies can show associations but are confounded by age, lifestyle and other illness. Check whether a result is about prevention or treatment, the baseline risk of participants, and the absolute rather than only the relative size of any benefit.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Real-World Usage of a Paclitaxel-Coated Balloon With Urea Compared With Other Contemporary Drug-Coated Balloons: A 2-Year Analysis From SCAAR in Over 6000 Patients | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 42216271 · DOI · PMC13315143 |
| ADAMTS13 Gene Polymorphisms and Coronary Artery Disease Risk, Long-Term Survival, and Risk Factor Profile | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 42194965 · DOI · PMC13205630 |
| Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 42554421 · DOI · PMC13651923 |
Real-World Usage of a Paclitaxel-Coated Balloon With Urea Compared With Other Contemporary Drug-Coated Balloons: A 2-Year Analysis From SCAAR in Over 6000 Patients [1]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundDrug-coated balloons (DCB) are frequently used during percutaneous coronary intervention.
- Closing excerpt
- This data further support the safety and efficacy of the PCB with urea.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (305 words)
BackgroundDrug-coated balloons (DCB) are frequently used during percutaneous coronary intervention. Despite this there are limited data from studies comparing different types of DCB, particularly for a paclitaxel-coated balloon (PCB) using urea as the excipient. This study aimed to assess the clinical efficacy of the PCB with urea compared with other frequently used DCB, attempting to emulate a target trial using observational data.MethodsSCAAR (Swedish Coronary Angiography and Angioplasty Registry) is a nationwide registry including data on all patients in Sweden undergoing coronary angiography. For this study, all procedures with DCB in Sweden between August 2021 and May 2024 were included. Propensity score weighted multivariable Cox regression analysis and Kaplan-Meier estimates were used to assess outcomes through 2 years.ResultsA total of 1797 (27.7%) procedures with the PCB with urea and 4691 (72.3%) procedures with Other DCB were eligible for this analysis. DCB treatment was performed in a variety of patients and lesions including 32.4% diabetes, 64.2% acute coronary syndrome, 20.5% bifurcations and 33.0% in-stent restenosis. After 2 years, the event rates for the PCB with urea and Other DCB were 16.4% versus 18.4% for major adverse cardiovascular events (hazard ratio [HR] 1.01 [95% CI 0.84-1.22]), 7.2% versus 8.2% for all-cause mortality (HR 1.05 [95% CI 0.80-1.39]), 6.1% versus 8.0% for myocardial infarction (HR 0.81 [95% CI 0.59-1.11]), 14.6% versus 14.9% for new revascularization with percutaneous coronary intervention (HR 1.02 [95% CI 0.83-1.25]), 0.8% versus 1.3% for target lesion definite thrombosis (HR 0.93 [95% CI 0.41-2.11]), 7.4% versus 8.7% for target lesion revascularization (HR 0.95 [95% CI 0.70-1.29]), and 10.5% versus 11.3% for target vessel revascularization (HR 0.99 [95% CI 0.76-1.29]).ConclusionsIn this analysis evaluating 2-year clinical outcomes after DCB, in a broad patient population, the PCB with urea had comparable outcomes with other contemporary DCB. This data further support the safety and efficacy of the PCB with urea.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42216271 · DOI · PMC13315143
ADAMTS13 Gene Polymorphisms and Coronary Artery Disease Risk, Long-Term Survival, and Risk Factor Profile [2]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundADAMTS13 is a protein that cleaves large multimers of von Willebrand factor, thereby limiting platelet aggregation and adhesion and regulating thrombogenesis.
- Closing excerpt
- A significant association between the analyzed polymorphisms and HDL levels or some proatherogenic lipid indices was observed; however, the underlying mechanism requires further investigation.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (195 words)
BackgroundADAMTS13 is a protein that cleaves large multimers of von Willebrand factor, thereby limiting platelet aggregation and adhesion and regulating thrombogenesis. Research findings suggest a possible association between low ADAMTS13 levels and an increased risk of cardiovascular events, and its activity may be influenced by polymorphic variants of the ADAMTS13 gene.MethodsThe study group included 259 patients diagnosed with coronary artery disease (CAD) and 238 control blood donors. Genotyping of ADAMTS13 polymorphisms (rs2301612, rs2073932, and rs2285489) was performed using TaqMan PCR.ResultsADAMTS13 gene polymorphisms showed no association with CAD risk or patient survival at 5- or 10-year follow-up. However, higher HDL cholesterol levels were observed in carriers of the G alleles (rs2301612 and rs2073932) and the T allele (rs2285489). Additionally, the rs2285489 and rs2301612 polymorphisms were associated with certain proatherogenic lipid indices. In silico analysis indicated that all studied polymorphisms influenced gene expression in certain vascular tissues or blood.ConclusionsADAMTS13 gene polymorphisms may affect gene expression in specific tissues; however, this effect does not appear sufficient to meaningfully influence CAD onset or patient survival. A significant association between the analyzed polymorphisms and HDL levels or some proatherogenic lipid indices was observed; however, the underlying mechanism requires further investigation.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42194965 · DOI · PMC13205630
Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundCoronary artery disease (CAD) is common in cirrhosis patients because of shared risk factors, including metabolic syndrome and alcohol use; however, outcomes after percutaneous coronary intervention (PCI) remain poorly defined.
- Closing excerpt
- Antiplatelet monotherapy after 30 days was associated with less bleeding and improved survival, supporting abbreviated DAPT in this high-risk group.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (165 words)
BackgroundCoronary artery disease (CAD) is common in cirrhosis patients because of shared risk factors, including metabolic syndrome and alcohol use; however, outcomes after percutaneous coronary intervention (PCI) remain poorly defined.AimsTo evaluate outcomes after PCI in patients with cirrhosis.MethodsWe conducted a retrospective cohort study using TriNetX US Collaborative Network data from 2015 to 2024. Adults undergoing PCI were stratified by cirrhosis status, with outcomes including gastrointestinal bleeding, ischaemic events, and all-cause mortality. Within the cirrhosis cohort, we evaluated effect modification by aetiology, disease severity, and antiplatelet strategy at 30 days after PCI. One-to-one propensity score matching adjusted for demographics and comorbidities, with results reported as relative risks and 95% confidence intervals.ResultsAmong 3351 patients with cirrhosis undergoing PCI matched 1:1 to controls, cirrhosis was associated with higher 1-year gastrointestinal bleeding (16.14% vs. 8.12%; p ConclusionCirrhosis confers substantially higher bleeding and mortality after PCI, particularly in decompensated disease. Antiplatelet monotherapy after 30 days was associated with less bleeding and improved survival, supporting abbreviated DAPT in this high-risk group.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42554421 · DOI · PMC13651923
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events [4]
- Research article Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis [5]
- Research article Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification [6]
- Research article The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis [7]
- Research article Coronary Plaque Characteristics Associated With Major Adverse Cardiovascular Events in Atherosclerotic Patients and Lesions: A Systematic Review and Meta-Analysis [8]
- Research article Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies [9]
References
- von Koch S, Frank E, Gabrysch K, James S, Götberg M, Mohammad MA, et al.. Real-World Usage of a Paclitaxel-Coated Balloon With Urea Compared With Other Contemporary Drug-Coated Balloons: A 2-Year Analysis From SCAAR in Over 6000 Patients. . 2026. PMID 42216271 · DOI · PMC13315143
- Wrona J, Balcerzyk-Matić A, Mizia-Stec K, Filipecki A, Krauze J, Niemiec P. ADAMTS13 Gene Polymorphisms and Coronary Artery Disease Risk, Long-Term Survival, and Risk Factor Profile. . 2026. PMID 42194965 · DOI · PMC13205630
- Gala D, Rao S, Gunani M, Shah K, Kulkarni AV, Wijarnpreecha K, et al.. Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. . 2026. PMID 42554421 · DOI · PMC13651923
- Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al.. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol. 2023. PMID 37407118 · DOI
- Mosquera JV, Auguste G, Wong D, Turner AW, Hodonsky CJ, Alvarez-Yela AC, et al.. Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis. Cell Rep. 2023. PMID 37950869 · DOI · PMC12335892
- Kavousi M, Bos MM, Barnes HJ, Lino Cardenas CL, Wong D, Lu H, et al.. Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification. Nat Genet. 2023. PMID 37770635 · DOI · PMC10601987
- Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, Amani-Beni R. The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis. Cardiovasc Diabetol. 2024. PMID 38566139 · DOI · PMC10986012
- Gallone G, Bellettini M, Gatti M, Tore D, Bruno F, Scudeler L, et al.. Coronary Plaque Characteristics Associated With Major Adverse Cardiovascular Events in Atherosclerotic Patients and Lesions: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2023. PMID 37804276 · DOI
- Assempoor R, Daneshvar MS, Taghvaei A, Abroy AS, Azimi A, Nelson JR, et al.. Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies. Cardiovasc Diabetol. 2025. PMID 39844262 · DOI · PMC11756160
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.